InvestorsHub Logo
Followers 44
Posts 10434
Boards Moderated 0
Alias Born 01/13/2016

Re: Jonjones325 post# 78565

Monday, 10/24/2016 8:58:20 AM

Monday, October 24, 2016 8:58:20 AM

Post# of 455329
Not qualified to answer. Risk of
Younger patient is the point..
I don't know enough about Rett Syndrome either.
With elderly PArkinsons and ADS population
The risk return on almost any treatment may be justified, but if you are dealing with a population whose life is not being immediately threatened, than you need to be more cautious from a patient and company perspective.
We all feel very confident that A2-73 poses limited if not zero risk as a small molecule, sigma 1 agonist.. and Pharmkokinetics may also add to this belief, but the best way at this point to actually demonstrate safety is through in human trials. I am willing to sign up right now! Bet you could find a few million more at the drop of a pin..Anavexnow!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News